WILLIAM H. STEELE, District Judge.
This matter comes before the Court on plaintiff's Motion to Enjoin Copycat Class Action (doc. 31). The Court has also reviewed and considered defendant's Response (doc. 33).
Plaintiff, Family Medicine Pharmacy, LLC, brought this putative class action against defendant, Impax Laboratories, Inc., alleging violations of the Telephone Consumer Protection Act of 1991, 47 U.S.C. § 227, as amended by the Junk Fax Prevention Act of 2005 (the "TCPA"). In particular, Family Medicine maintains that it received an unsolicited "junk fax" advertising an Impax pharmaceutical product, in violation of the TCPA's prohibition on transmission of unsolicited advertisements by facsimile, computer, or other device. See 47 U.S.C. § 227(b)(1)(C). Family Medicine filed its Class Action Complaint (doc. 1) on January 30, 2017, seeking certification of a class defined as "[a]ny and all individuals and entities, who or which, from 2013 to the present, received one or more unsolicited advertisements via facsimile from Defendant." (Doc. 1, ¶ 19.)
In its Motion, plaintiff alleges that on February 14, 2017, more than two weeks after Family Medicine filed this Complaint, another entity called Medicine To Go Pharmacies, Inc., filed a "copycat class action complaint" against Impax in the United States District Court for the District of New Jersey, alleging the same TCPA violations arising from the same or substantially similar fax advertisements (the "Medicine To Go Action"). Citing the "first-to-file rule," Family Medicine urges this Court to enjoin the Medicine To Go Action and says that the undersigned has authority to enjoin the New Jersey federal proceedings pursuant to the All Writs Act, 28 U.S.C. § 1651.
Conspicuously absent from the Motion to Enjoin is any indication that Family Medicine has asked the U.S. District Court for the District of New Jersey to enjoin the Medicine To Go Action in accordance with the first-to-file rule, much less that the New Jersey court has been unsympathetic or has otherwise expressed unwillingness to grant such relief. In essence, then, Family Medicine is petitioning this Court to enjoin and interfere with the operations of a sister federal district court without any indication that the sister court is doing anything to frustrate this Court's orders or the exercise of its jurisdiction in this matter. This Court is empowered to enter such an injunction in appropriate circumstances.
At any rate, the Court understands that Impax has petitioned the New Jersey court in the Medicine To Go Action to dismiss, stay or transfer that case to this District Court. Given these circumstances, the most prudent course of action is to allow the New Jersey court to decide that motion without judicial interference by a coordinate court, rather than charging into the fray before that court has an opportunity to adjudicate Impax's request. For that reason, and under principles of comity and institutional orderliness, Family Medicine's Motion to Enjoin Copycat Class Action (doc. 31) is
DONE and ORDERED.